secwatch.observer — SEC 8-K summary
======================================

Issuer:     Jazz Pharmaceuticals plc (JAZZ)
CIK:        0001232524
Form:       8-K
Filed at:   2025-04-21T23:59:59+00:00
Accession:  0001193125-25-087233
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.70
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Jazz completes $935M acquisition of Chimerix, adds dordaviprone to pipeline
---------------------------------------------------------------------------

- Acquisition completed for ~$935M cash; $8.55 per share.
- Dordaviprone for H3 K27M-mutant diffuse glioma under FDA Priority Review; PDUFA date Aug 18, 2025.
- If approved, could be first FDA-approved therapy for that indication; potential near-term opportunity.
- Also in Phase 3 ACTION trial for newly diagnosed, non-recurrent diffuse glioma.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1232524/000119312525087233/0001193125-25-087233-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1232524/000119312525087233/d887871d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-087233

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer